These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11839646)

  • 1. Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002.
    Lippman SM; Hong WK
    Clin Cancer Res; 2002 Feb; 8(2):305-13. PubMed ID: 11839646
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary re: N. J. McCarthy et al., microvessel density, expression of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflammatory breast cancer. Clin. Cancer Res., 8: 3857-3862, 2002.
    Colpaert CG; Vermeulen PB; Dirix LY; Van Marck EA
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3815-6; author reply 3816. PubMed ID: 14506176
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
    Kashfi K; Rigas B
    Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002.
    Siwak DR; Tari AM; Lopez-Berestein G
    Clin Cancer Res; 2002 Apr; 8(4):955-6. PubMed ID: 11948099
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged.
    Tang YC; Thoman M; Linton PJ; Deisseroth A
    Cancer Immunol Immunother; 2009 Dec; 58(12):1949-57. PubMed ID: 19444444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview.
    Crowell JA
    Eur J Cancer; 2005 Sep; 41(13):1889-910. PubMed ID: 16005206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correspondence re: K. Heer et al., serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin. Cancer Res., 7: 3491-3494, 2001.
    Murphy CE; Lansdown MR; Speirs V; Carder PJ
    Clin Cancer Res; 2003 Aug; 9(9):3514; author reply 3515. PubMed ID: 12960144
    [No Abstract]   [Full Text] [Related]  

  • 8. Correspondence re: S. A. W. Fuqua et al., Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res.,63: 2434-2439, 2003.
    Speirs V
    Cancer Res; 2003 Dec; 63(24):9055. PubMed ID: 14695225
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy.
    Guadagni F; Ferroni P; Palmirotta R; Del Monte G; Formica V; Roselli M
    Anticancer Res; 2007; 27(5A):3147-62. PubMed ID: 17970056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New HER2-directed therapies for breast cancer. Commentary re: C. I. Spiridon et al., Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity. Clin. Cancer Res., 8: 1720-1730, 2002.
    Frankel AE
    Clin Cancer Res; 2002 Jun; 8(6):1699-701. PubMed ID: 12060606
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer.
    Pereg D; Lishner M
    J Intern Med; 2005 Aug; 258(2):115-23. PubMed ID: 16018788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoresistance: impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Commentary re J. Guo et al., Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the NF-kappaB p65 subunit. Clin Cancer Res 2004;10:3333-3341.
    Veiby OP; Read MA
    Clin Cancer Res; 2004 May; 10(10):3262-4. PubMed ID: 15161678
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
    Dalton WS
    Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
    [No Abstract]   [Full Text] [Related]  

  • 14. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003.
    Rundhaug JE
    Clin Cancer Res; 2003 Feb; 9(2):551-4. PubMed ID: 12576417
    [No Abstract]   [Full Text] [Related]  

  • 15. Correspondence re: A. Kumar et al., cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res., 61: 7552-7555, 2001.
    Garattini E; Gianni' M; Terao M
    Cancer Res; 2002 Apr; 62(7):2192-3; author reply 2193-4. PubMed ID: 11929843
    [No Abstract]   [Full Text] [Related]  

  • 16. [Non-steroidal anti-inflammatory agents and prevention of colorectal cancer and other types of cancer].
    Sørensen HT; Nørgård B; Friis S; Laurberg S; Olsen JH; Kronberg O
    Ugeskr Laeger; 2003 Mar; 165(12):1260-1. PubMed ID: 12701310
    [No Abstract]   [Full Text] [Related]  

  • 17. Suppression of met expression: a possible cancer treatment. Commentary re: S. J. Kim et al., reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin. Cancer Res., 14: 5161-5170, 2003.
    Shinomiya N; Vande Woude GF
    Clin Cancer Res; 2003 Nov; 9(14):5085-90. PubMed ID: 14613985
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary on neostigmine interactions with non steroidal anti-inflammatory drugs by Miranda et al.
    Tallarida RJ
    Br J Pharmacol; 2002 Apr; 135(7):1589-90. PubMed ID: 11934797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
    Lippman SM; Heymach JV
    Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
    Andrews P; Zhao X; Allen J; Li F; Chang M
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.